SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas

ConditionsHuman Papillomavirus Associated Carcinomas Cervical Cancer Head and Neck Cancers Anal Cancer Vulva Cancer Vaginal Cancer Penile Cancer HPV-Related Malignancy

Trial statusRecruiting

Trial phasePhase 1

Trial typeInterventional

Biological sexAll

Age18+

SponsorThe Affiliated Hospital of Qingdao University

About this trial

A multicenter, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of SCG142 TCR-T cells in Subjects with advanced HPV associated carcinomas.

Eligibility criteria

Qualifiers

Greater than or equal to 18 years of age

HPV associated carcinomas

Patients must have at least one measurable lesion defined by RECIST 1.1

Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

Disqualifiers

Active or uncontrollable infections or other active major medical illnesses of the cardiovascular, respiratory.

Patients with active autoimmune diseases.

Patient has a known active Hepatitis B or Hepatitis C.

Other severe medical conditions that may limit subject's participation in this trial.

Trial design

Treatments tested in this trial

SCG142 TCR-T cells

Treatment groups

18 Participants

are divided into 1 treatment group

Sponsors and collaborators

The Affiliated Hospital of Qingdao University

Lead sponsor

Source ClinicalTrials.gov